Arbutus Announces Multiple Abstracts Highlighting Imdusiran Data Accepted for Presentation at AASLD - The Liver Meeting® 2024
October 15, 2024 08:16 ET
|
Arbutus Biopharma Corporation
WARMINSTER, Pa., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”) a clinical-stage biopharmaceutical company leveraging its extensive...
Arbutus Presents AB-729 Clinical Data and AB-101 Preclinical Data at AASLD - The Liver Meeting®
November 01, 2022 16:01 ET
|
Arbutus Biopharma Corporation
HBsAg and HBV DNA remain at low levels with no evidence of clinical relapse up to 44 weeks after discontinuing AB-729 and NA therapy Preclinical data suggest that AB-101, an oral PD-L1 inhibitor, in...
Arbutus to Present Seven Scientific Posters at EASL International Liver Congress™ 2022
June 08, 2022 02:05 ET
|
Arbutus Biopharma Corporation
Conference Call & Webcast to discuss new data being presented at EASL ILC 2022 scheduled for June 27, 2022 at 8:00 am ETWARMINSTER, Pa., June 08, 2022 (GLOBE NEWSWIRE) -- Arbutus Biopharma...
Data Highlighted From 3 Studies Demonstrate Complementarity of BioNano Genomics’ Next-Generation Mapping to Sequencing
January 11, 2016 07:00 ET
|
Bionano Genomics
SAN DIEGO, Jan. 11, 2016 (GLOBE NEWSWIRE) -- BioNano Genomics, the leader in physical genome mapping, today announced data from three studies demonstrating how next-generation mapping (NGM) using...